SUBSCRIBE
SUBSCRIBE

Johnson & Johnson Family of Companies

NEWS
Policy
How Much Does Johnson & Johnson Spend on Lawsuits Every Year?
March 10, 2015
 · 
1 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
AbbVie, Johnson & Johnson Tempted to Take Over $650 Million Galapagos
March 10, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
AbbVie Outbids Johnson & Johnson and Lands Pharmacyclics for $21 Billion
March 5, 2015
 · 
2 min read
CALBIO15:
Job Trends
CALBIO15: Johnson & Johnson Unveils New Innovation Center, Looks to Spark Creative Revolution in the Bay: Exec
March 3, 2015
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
Cardinal Health Ponies Up $1.944 Billion Cash for Johnson & Johnson’s Cordis
March 2, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Bay Area’s Pharmacyclics Mulls Possible $18 Billion Sale; Johnson & Johnson,Novartis AG Interested
February 26, 2015
 · 
2 min read
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Pharm Country
Johnson & Johnson Launches Three Ambitious R&D Projects Aimed to Spot Who’ll Get a Disease
February 12, 2015
 · 
2 min read
Biotech Bay
Drugmakers Like GlaxoSmithKline, Johnson & Johnson, And Novartis AG Break Away From Its Old Ways
February 9, 2015
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
FDA
FDA Green Lights Bristol-Myers Squibb Company, Johnson & Johnson HIV Pills
January 30, 2015
 · 
2 min read
Load More
AWARDS
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies
December 29, 2025
 · 
5 min read
Press Releases
European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor
December 22, 2025
 · 
14 min read
Press Releases
Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma
December 19, 2025
 · 
6 min read
Press Releases
U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib)
December 18, 2025
 · 
33 min read
Press Releases
Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results - December 15, 2025
December 16, 2025
 · 
1 min read
Press Releases
Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
December 16, 2025
 · 
4 min read
Press Releases
U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*
December 15, 2025
 · 
20 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
18 min read
Press Releases
Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma
December 10, 2025
 · 
28 min read
Press Releases
Johnson & Johnson to Participate in the 44th Annual J.P. Morgan Healthcare Conference
December 9, 2025
 · 
1 min read
Load More